NIPH Clinical Trials Search

Effective and safe examination of teneligliptin for the type 2 diabetes with dialysis patient

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	type 2 diabetes with dialysis patient
Date of first enrollment	2013/09/30
Target sample size	10
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Teneligliptin 20mg/day 12 week

Outcome(s)

Primary Outcome	The Change of HbA1c, GA, FPG after 12 weeks
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	65years-old
Gender	Male and Female
Include criteria
Exclude criteria	1)Type 1 diabetes,diabetes arising from the failure of pancreas,or secondary diabetes (eg. Cushing's syndrome and acromegaly) 2) Patient correspond to contraindications of teneligliptin 3) Excessive alcohol addicts: patient who take average net more than 60 g alcohol every single day (more than following: 3 bottles of sake, 1 with shochu, 3 bottles of beer, 3 glasses of whiskey or brandy(double),and 5 glasses of wine) 4) Pregnant, lactating, possible pregnant patient 1)Type 1 diabetes,diabetes arising from the failure of pancreas,or secondary diabetes (eg. Cushing's syndrome and acromegaly) 2) Patient correspond to contraindications of teneligliptin 3) Excessive alcohol addicts: patient who take average net more than 60 g alcohol every single day (more than following: 3 bottles of sake, 1 with shochu, 3 bottles of beer, 3 glasses of whiskey or brandy(double),and 5 glasses of wine) 4) Pregnant, lactating, possible pregnant patient 5) Patient judged as ineligible for this study by the researcher